Abstract:IntroductionImmunotherapy is changing the standard of care in cancer treatment. Immune checkpoint blockers (ICBs) that block the checkpoint programs used by tumor cells to inhibit the immune response have been approved by the US Food and Drug Administration with varying efficacy across cancer types. Given the clear benefits of ICB in some patients, there is an urgent research need to understand the determinants of ICB efficacy so more patients can benefit. To this end, there is growing interest in the interactions between immune cells and tumor cells as well as other extrinsic factors that can impact ICB therapy. Recent studies have shown that the microbiome can modulate the efficacy of immunotherapy. Specifically, clinical and therapeutic outcomes improved in a subset of ICB-refractory patients treated with fecal microbiota transplants (FMTs) from melanoma patients who responded to ICB therapy in combination with additional cycles of ICB therapy suggesting a synergistic effect of the gut microbiome. However, there is limited information and often inconsistencies among studies about the effect of bacteria on the immune system and checkpoint immunotherapy.MethodologyTo study the mechanisms by which the gut microbiome affects components of the immune system and response to ICB, we developed a mechanistic mathematical model for tumor growth in terms of immune components as features. The model simulates the temporal changes in the immune system during tumor progression and checkpoint immunotherapy. More specifically, the model simulates the tumor cells, relevant immune cells, and cytokines. The model was used for the reproduction of tumor growth curves from several preclinical FMT studies with ICB treatment. To determine the possible effect of the microbiome on the immune components, existing statistical approaches were used between experimental microbiome data and the immune components of the model.ResultsThe mathematical model was able to reproduce the experimental tumor growth curves by varying only two critical parameters. These parameters identify two possible mechanisms by which the gut microbiome can influence the immune response: i) the killing potential of tumor cells by immune cells and ii) the activation of the adaptive immune system. Furthermore, the model predictions agree with the observation that ICB treatment is only effective with FMT from responder patients. Additionally, the association analysis was able to identify specific microbes that induce positive and negative effects for ICB, and how these microbes affect various components of the immune system.ConclusionOur analysis identifies possible mechanisms by which the microbiome affects checkpoint immunotherapy and predicts not only which constituents of the microbiome have positive and negative effects but also identifies how these microbes are related to immune mechanisms. This information could be valuable for designing future targeted studies to validate these possible mechanisms at the cell and molecular levels. Citation Format: Constantinos Harkos, Andreas Hadjigeorgiou, Aditya K. Mishra, Golnaz Morad, Sarah Johnson, Nadim J. Ajami, Triantafyllos Stylianopoulos, Lance L. Munn, Jeniffer A. Wargo, Rakesh K. Jain. Modulation of cancer immunotherapy by the microbiome: Insights from computational analyses of preclinical studies [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl) nr B39.

Abstract A037: Mathematical modeling of the tumor-immune microenvironment in murine colon adenocarcinoma

Abstract 2872: Site specific tumor microenvironments modulate the immune checkpoint inhibitors response in models of CT26 colon carcinoma

Abstract IA01: Modeling and understanding tumor biologic mechanisms

Abstract 3176: Modeling the complex multi-cellular ecosystem of the tumor microenvironment in colorectal cancer using multi-omics data

Abstract IA020: Microphysiological systems to decipher tumor-stromal interactions in colorectal cancer

Abstract 77: Recapitulating metastatic colorectal cancer in somatic mutation models for investigating the tumor immune microenvironment in minimal residual disease

Abstract B39: Modulation of cancer immunotherapy by the microbiome: Insights from computational analyses of preclinical studies

Abstract A122: Deciphering macrophage targeting cancer immunotherapies using a novel in vitro assay modelling the tumor microenvironment

Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment

Abstract A023: Integrating mathematical modeling and in vitro experiments to measure ecological interactions in cancer

Abstract 239: Establishing a murine intratumoral bacterial model

Abstract 2048: Integrated tumor models for immune oncology: Using live cell imaging for prediction of treatment efficacy in vitro and in vivo

Abstract 6930: Spatial analysis of multi-ancestral tumors to understand how intercellular signaling impacts tumor invasion

Abstract 1657: Syngeneic tumor development, treatment responses and immune infiltrate in subcutaneous and orthotopic mouse models

Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells

Modeling and understanding tumor biologic mechanisms.

Abstract 5493: Mathematical modeling of antibody nanoconjugates transport quantifies the impact of the tumor microenvironment on drug penetration

Modelling the tumor immune microenvironment for precision immunotherapy

Abstract 3874: Monitoring immune-tumor cell interactions in 3D microfluidic models with optical metabolic imaging and molecular profiling

Abstract 4600: Phenotypic & functional diversity of tumor associated neutrophils in murine breast tumor models

Abstract IA019: Multiscale systems approach to target tumor ecosystem responses for therapeutic benefit